Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-ALPP CAR-T cells in ALPP-positive advanced solid tumors
NCT07108140Phase 1Terminated
- Sponsor
- TCRCure Biotech
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALPP CAR-T in solid tumor, sponsored by TCRCure Biotech. Primary endpoint: Safety of ALPP CAR-T cells at 24 months. Started May 2025; status: terminated.
02
Drugs
ALPP CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07108140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108140.